hVIVO engages in major phase 2b influeness drug study as exclusive UK clinical site
hVIVO plc (AIM & Euronext: HVO), a rapidly expanding specialist contract research organisation (CRO) renowned for its expertise in human challenge clinical trials for infectious ... Read More
Oncocross and JW Pharmaceutical forge new path in AI-driven drug development
In a significant stride toward revolutionizing drug discovery and development, Seoul-based biotech firm Oncocross announced on May 22nd a renewed joint research agreement with JW ... Read More